PTGX Quote, Financials, Valuation and Earnings

Precision BioSciences has a net margin of -710.37% compared to Protagonist Therapeutics's net margin of -2851.56%. Protagonist Therapeutics's return on equity of 37.59% beat Precision BioSciences's return on equity of 19.19%.

Protagonist Therapeutics has a consensus price target of --, signalling upside risk potential of 47.59%. On the other hand Precision BioSciences has an analysts' consensus of $33.60 which suggests that it could grow by 622.58%. Given that Precision BioSciences has higher upside potential than Protagonist Therapeutics, analysts believe Precision BioSciences is more attractive than Protagonist Therapeutics.

Protagonist Therapeutics has a beta of 2.178, which suggesting that the stock is 117.841% more volatile than S&P 500. In comparison Precision BioSciences has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.772%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Precision BioSciences pays out -- of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $4.7M, which are larger than Precision BioSciences quarterly revenues of $576K. Protagonist Therapeutics's net income of -$33.2M is lower than Precision BioSciences's net income of -$16.4M. Notably, Protagonist Therapeutics's price-to-earnings ratio is 14.65x while Precision BioSciences's PE ratio is 77.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 7.43x versus 0.36x for Precision BioSciences. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -710.37% compared to Protagonist Therapeutics's net margin of -49.65%. Protagonist Therapeutics's return on equity of 37.59% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Protagonist Therapeutics has a consensus price target of --, signalling upside risk potential of 47.59%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 546.03%. Given that NovaBay Pharmaceuticals has higher upside potential than Protagonist Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Protagonist Therapeutics.

Protagonist Therapeutics has a beta of 2.178, which suggesting that the stock is 117.841% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $4.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Protagonist Therapeutics's net income of -$33.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Protagonist Therapeutics's price-to-earnings ratio is 14.65x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 7.43x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -710.37% compared to Protagonist Therapeutics's net margin of -2357.27%. Protagonist Therapeutics's return on equity of 37.59% beat Palatin Technologies's return on equity of --.

Protagonist Therapeutics has a consensus price target of --, signalling upside risk potential of 47.59%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Protagonist Therapeutics, analysts believe Palatin Technologies is more attractive than Protagonist Therapeutics.

Protagonist Therapeutics has a beta of 2.178, which suggesting that the stock is 117.841% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $4.7M, which are larger than Palatin Technologies quarterly revenues of $350K. Protagonist Therapeutics's net income of -$33.2M is lower than Palatin Technologies's net income of -$7.8M. Notably, Protagonist Therapeutics's price-to-earnings ratio is 14.65x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 7.43x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics has a net margin of -710.37% compared to Protagonist Therapeutics's net margin of -71.7%. Protagonist Therapeutics's return on equity of 37.59% beat Entrada Therapeutics's return on equity of 17.06%.

Protagonist Therapeutics has a consensus price target of --, signalling upside risk potential of 47.59%. On the other hand Entrada Therapeutics has an analysts' consensus of -- which suggests that it could grow by 51.8%. Given that Entrada Therapeutics has higher upside potential than Protagonist Therapeutics, analysts believe Entrada Therapeutics is more attractive than Protagonist Therapeutics.

Protagonist Therapeutics has a beta of 2.178, which suggesting that the stock is 117.841% more volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Protagonist Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protagonist Therapeutics pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

Protagonist Therapeutics quarterly revenues are $4.7M, which are smaller than Entrada Therapeutics quarterly revenues of $19.6M. Protagonist Therapeutics's net income of -$33.2M is lower than Entrada Therapeutics's net income of -$14M. Notably, Protagonist Therapeutics's price-to-earnings ratio is 14.65x while Entrada Therapeutics's PE ratio is 10.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protagonist Therapeutics is 7.43x versus 2.92x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.